CLAIMS

1. A pharmaceutical composition for use in the treatment of injury of the spinal cord, which comprises an HMGB1 fragment peptide selected from the group consisting of:
a) a fragment peptide comprising at least the fragment peptide of SEQ ID NO: 3 with the upper limit being the fragment peptide of SEQ ID NO: 4;
b) a fragment peptide comprising at least the fragment peptide of SEQ ID NO: 4 with the upper limit being the fragment peptide of SEQ ID NO: 5; and
c) a fragment peptide comprising at least the fragment peptide of SEQ ID NO: 3 with the upper limit being the fragment peptide of SEQ ID NO: 5.

~~2. The pharmaceutical composition of claim 1, wherein the HMGB1 fragment peptide is a peptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 3, SEQ ID NO: 4, and SEQ ID NO: 5.~~

~~3~~2. The pharmaceutical composition of claim 1, wherein the HMGB1 fragment peptide is a peptide consisting of ~~an~~the amino acid sequence selected from the group consisting of SEQ ID NO: 3, SEQ ID NO: 4, and SEQ ID NO: 5.

~~4~~3. Use of ~~a pharmaceutical composition comprising~~ an HMGB1 fragment peptide in the manufacture of a medicament for the treatment of injury of the spinal cord, wherein the HMGB1 fragment peptide is selected from the group consisting of:
a) a fragment peptide comprising at least the fragment peptide of SEQ ID NO: 3 with the upper limit being the fragment peptide of SEQ ID NO: 4;
b) a fragment peptide comprising at least the fragment peptide of SEQ ID NO: 4 with the upper limit being the fragment peptide of SEQ ID NO: 5; and
c) a fragment peptide comprising at least the fragment peptide of SEQ ID NO: 3 with the upper limit being the fragment peptide of SEQ ID NO: 5.

~~5. The use of claim 4, wherein the HMGB1 fragment peptide is a peptide comprising the amino acid sequence selected from the group consisting of SEQ ID NO: 3, SEQ ID NO: 4, and SEQ ID NO: 5.~~

~~6~~4. The use of claim ~~4~~3, wherein the HMGB1 fragment peptide is a peptide consisting of the amino acid sequence selected from the group consisting of SEQ ID NO: 3, SEQ ID NO: 4, and SEQ ID NO: 5.

[6] the method of [4], wherein the HMGB1 fragment peptide is a peptide consisting of the amino acid sequence selected from the group consisting of SEQ ID NO: 3, SEQ ID NO: 4, and SEQ ID NO: 5;

In one aspect, there is provided a pharmaceutical composition for use in the treatment of injury of the spinal cord, which comprises an HMGB1 fragment peptide selected from the group consisting of: a) a fragment peptide comprising at least the fragment peptide of SEQ ID NO: 3 with the upper limit being the fragment peptide of SEQ ID NO: 4; b) a fragment peptide comprising at least the fragment peptide of SEQ ID NO: 4 with the upper limit being the fragment peptide of SEQ ID NO: 5; and c) a fragment peptide comprising at least the fragment peptide of SEQ ID NO: 3 with the upper limit being the fragment peptide of SEQ ID NO: 5.

In another aspect, there is provided the use of ~~a pharmaceutical composition comprising~~ an HMGB1 fragment peptide in the manufacture of a medicament for the treatment of injury of the spinal cord, wherein the HMGB1 fragment peptide is selected from the group consisting of:
a) a fragment peptide comprising at least the fragment peptide of SEQ ID NO: 3 with the upper limit being the fragment peptide of SEQ ID NO: 4;
b) a fragment peptide comprising at least the fragment peptide of SEQ ID NO: 4 with the upper limit being the fragment peptide of SEQ ID NO: 5; and
c) a fragment peptide comprising at least the fragment peptide of SEQ ID NO: 3 with the upper limit being the fragment peptide of SEQ ID NO: 5.